Aurealis Therapeutics novel chronic wound treatment to be presented at the 4th Experts Meeting on Microbiome & Skin Health and Disease 2020
Haritha Samaranayake, MD, PhD, Medical Director of Aurealis Therapeutics will give a talk about development of AUP16, the company´s lead product for non-healing wounds such as diabetic foot ulcer. The presentation is titled “Development of a Live Biotherapeutic to treat diabetic foot ulcer“ and is scheduled for Tuesday, December 15th, 2020 at 14:30 CET. More […]
Aurealis Therapeutics has initiated repeated dosing groups in the AUP-16 Phase 1 Diabetic Foot Ulcer clinical trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company, is making a difference in chronic, non-healing wounds by developing a therapy with multiple active substances in one product that are hitting all key pathomechanisms. Chronic wound care needs curative drugs with true active pharmaceutical substances, not just incrementally improved dressings and devices. The company announced today that […]
Aurealis Therapeutics to strengthen its Board of Directors by appointing Laurent Décory
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the four-in-one biologic drug for chronic non-healing wounds and regenerative diseases, announced today that Mr. Laurent Décory has joined the Board of Directors of the company as of June 10th, 2020. Existing Board Directors Iain Buchanan, Silvio Inderbitzin and Roger Meier were elected to continue along […]
Aurealis Therapeutics pioneering multiple drug producing bacteria AUP-16 dosed to the first diabetic foot ulcer patient in the Phase 1-2A trial
Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. The trial is performed in non-healing DFU patients and is designed to evaluate the safety, tolerability and preliminary efficacy […]
Aurealis Therapeutics receives Clinical Trial Application approval for AUP-16 Phase 1 DFU study
Aurealis Therapeutics, a private biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today clinical trial application (CTA) approval of the AUP-16 phase 1 diabetic foot ulcer (DFU) patient trial by the German Health Authority Paul-Ehrlich-Institute. The company plans to enroll the first patient to the phase […]
Aurealis Therapeutics announces 7.8MCHF financing to advance lead candidate AUP-16 for diabetic foot ulcers under new brand: Aurealis Therapeutics AG
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced 7.8MCHF funding provided by Swiss and foreign private investors, Finnvera plc, and Business Finland – the Finnish Innovation Funding Agency. The company also confirmed the de-merger and a plan to develop and commercialize the AUP-16 under a […]
Aurealis Therapeutics submits Clinical Trial Application for AUP-16 Phase 1 DFU study
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds and cancer announced today the successful submission of its first Clinical Trial Application (CTA) to the German Health Authority Paul-Ehrlich-Institute (PEI) for the lead development candidate AUP1602-C to be studied in a first-in-human phase 1-2A clinical study as treatment of […]
Aurealis Therapeutics to strengthen its Board of Directors by appointing Iain Buchanan
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that Mr. Iain Buchanan has joined the board of directors of the company as of May 16th 2018. Existing board members CSO and founder Mr. Thomas Wirth, senior life science executive, Mrs. Nora Kaarela, senior […]
Aurealis Therapeutics to present at the European Wound Management Association (EWMA) Congress 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CMO Dirk Weber will attend and discuss the company’s progress and clinical development plans for lead development product AUP-16 indicated for chronic wounds at the European Wound Management Association (EWMA) Congress in Krakow, Poland […]
Aurealis Therapeutics to attend the Swiss Biotech Day 2018
Aurealis Therapeutics, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic non-healing wounds, cancer and osteoarthritis announced today that CEO Juha Yrjänheikki and CMO Dirk Weber will attend and discuss the company’s progress at the Swiss Biotech Day in Basel on May 3rd 2018. The Swiss Biotech Day has long become the standard annual get-together […]
